Latest News and Press Releases

AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER'S THERAPY CRENEZUMAB Crenezumab higher dose in CREAD Phase 3 Alzheimer's trial supported by exposure-response model Phase 1b...

                   Lausanne, Switzerland, November 23, 2016 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today...

AC Immune Announces Results of Annual General Meeting Financial expert Mr. Thomas Graney elected as new member of the Board of Directors Shareholders approve all proposed resolutions of the...

LAUSANNE, Switzerland, Nov. 11, 2016 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced...

AC Immune Reports Third Quarter 2016 Results Successfully Completed Initial Public Offering on NASDAQ, Net Proceeds of $ 70.5 million (CHF 69.4 million)* Lausanne, Switzerland,...

SWITZERLAND'S AC IMMUNE OPENS FOR TRADING ON NASDAQ LAUSANNE, Switzerland, Sept. 23, 2016 (GLOBE NEWSWIRE) -- AC Immune SA, a Swiss-based, clinical stage biopharmaceutical company focused on...

SWITZERLAND'S AC IMMUNE OPENS FOR TRADING ON NASDAQ Lausanne, Switzerland, September 23, 2016 - AC Immune SA, a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative...

AC Immune Announces Pricing of Upsized Initial Public Offering Lausanne, Switzerland - September 23, 2016 - AC Immune SA announced today the pricing of its initial public offering of 6,000,000 of...

LAUSANNE, Switzerland, Sept. 13, 2016 (GLOBE NEWSWIRE) -- AC Immune SA announced today that it has commenced the initial public offering of 4,545,456 of its common shares pursuant to a registration...

AC Immune Commences Proposed Initial Public Offering of Common Shares Lausanne, Switzerland - September 13, 2016 - AC Immune SA announced today that it has commenced the initial public...